Increased concentrations of serum pentosidine in rheumatoid arthritis

The results prove that AGEs may accumulate in the absence of hyperglycemia or impaired kidney function, and increased concentrations of pentosidine in sera of patients with rheumatoid arthritis, systemic lupus erythematosus, and diabetes are measured.

Abstract

Advanced glycosylation end products (AGEs) are thought to play an important role in the development of diabetic complications. Oxidative reactions are essential for the formation of some AGEs, termed glycoxidation products. Increased concentrations of pentosidine, one of such products, are found in tissue and serum in diabetes mellitus and in end-stage renal disease, suggesting that hyperglycemia and impaired renal function are important factors in AGE accumulation. We hypothesized that increased concentrations of pentosidine would also be found in pathological conditions associated with increased oxidative stress. We measured pentosidine in sera of patients with rheumatoid arthritis (RA), systemic lupus erythematosus, and diabetes. Increased serum pentosidine was found in RA (108.4 +/- 146.5 nmol/L, P < 0.002) and in diabetes (69.6 +/- 42.4 nmol/L, P < 0.001) as compared with healthy subjects (48.3 +/- 12.0 nmol/L). These results prove that AGEs may accumulate in the absence of hyperglycemia or impaired kidney function.